183 related articles for article (PubMed ID: 33342421)
1. Possible Therapeutic Interventions in COVID-19 Induced ARDS by Cotinine as an ACE-2 Promoter and AT-1R Blocker.
Sharma T; Mehan S
Infect Disord Drug Targets; 2021; 21(6):e170721189261. PubMed ID: 33342421
[TBL] [Abstract][Full Text] [Related]
2. Increased Angiotensin-Converting Enzyme 2 and Loss of Alveolar Type II Cells in COVID-19-related Acute Respiratory Distress Syndrome.
Gerard L; Lecocq M; Bouzin C; Hoton D; Schmit G; Pereira JP; Montiel V; Plante-Bordeneuve T; Laterre PF; Pilette C
Am J Respir Crit Care Med; 2021 Nov; 204(9):1024-1034. PubMed ID: 34449302
[No Abstract] [Full Text] [Related]
3. Renin-Angiotensin System: An Important Player in the Pathogenesis of Acute Respiratory Distress Syndrome.
Hrenak J; Simko F
Int J Mol Sci; 2020 Oct; 21(21):. PubMed ID: 33126657
[TBL] [Abstract][Full Text] [Related]
4. [Lessons from SARS: a new potential therapy for acute respiratory distress syndrome (ARDS) with angiotensin converting enzyme 2 (ACE2)].
Imai Y; Kuba K; Penninger JM
Masui; 2008 Mar; 57(3):302-10. PubMed ID: 18340998
[TBL] [Abstract][Full Text] [Related]
5. Kallikrein-kinin blockade in patients with COVID-19 to prevent acute respiratory distress syndrome.
van de Veerdonk FL; Netea MG; van Deuren M; van der Meer JW; de Mast Q; Brüggemann RJ; van der Hoeven H
Elife; 2020 Apr; 9():. PubMed ID: 32338605
[TBL] [Abstract][Full Text] [Related]
6. Impact of ACE I gene insertion/deletion, A-240T polymorphisms and the renin-angiotensin-aldosterone system on COVID-19 disease.
Zobel CM; Kuhn H; Schreiner M; Wenzel W; Wendtland J; Goekeri C; Scheit L; Oltmanns K; Rauschning D; Grossegesse M; Hofmann N; Wirtz H; Spethmann S;
Virol J; 2024 Jan; 21(1):15. PubMed ID: 38200555
[TBL] [Abstract][Full Text] [Related]
7. Angiotensin-converting enzyme 2 protects from severe acute lung failure.
Imai Y; Kuba K; Rao S; Huan Y; Guo F; Guan B; Yang P; Sarao R; Wada T; Leong-Poi H; Crackower MA; Fukamizu A; Hui CC; Hein L; Uhlig S; Slutsky AS; Jiang C; Penninger JM
Nature; 2005 Jul; 436(7047):112-6. PubMed ID: 16001071
[TBL] [Abstract][Full Text] [Related]
8. The Impact of
Gintoni I; Adamopoulou M; Yapijakis C
In Vivo; 2022; 36(1):13-29. PubMed ID: 34972696
[TBL] [Abstract][Full Text] [Related]
9. Countermeasure and therapeutic: A(1-7) to treat acute respiratory distress syndrome due to COVID-19 infection.
Soto M; diZerega G; Rodgers KE
J Renin Angiotensin Aldosterone Syst; 2020; 21(4):1470320320972018. PubMed ID: 33169644
[TBL] [Abstract][Full Text] [Related]
10. The pivotal link between ACE2 deficiency and SARS-CoV-2 infection.
Verdecchia P; Cavallini C; Spanevello A; Angeli F
Eur J Intern Med; 2020 Jun; 76():14-20. PubMed ID: 32336612
[TBL] [Abstract][Full Text] [Related]
11. Effects of Angiotensin II Receptor Blockers and ACE (Angiotensin-Converting Enzyme) Inhibitors on Virus Infection, Inflammatory Status, and Clinical Outcomes in Patients With COVID-19 and Hypertension: A Single-Center Retrospective Study.
Yang G; Tan Z; Zhou L; Yang M; Peng L; Liu J; Cai J; Yang R; Han J; Huang Y; He S
Hypertension; 2020 Jul; 76(1):51-58. PubMed ID: 32348166
[TBL] [Abstract][Full Text] [Related]
12. Understanding the Pathophysiology of COVID-19: Could the Contact System Be the Key?
Meini S; Zanichelli A; Sbrojavacca R; Iuri F; Roberts AT; Suffritti C; Tascini C
Front Immunol; 2020; 11():2014. PubMed ID: 32849666
[TBL] [Abstract][Full Text] [Related]
13. Renin Angiotensin Aldosterone System Antagonism in 2019 Novel Coronavirus Acute Lung Injury.
Ventura D; Carr AL; Davis RD; Silvestry S; Bogar L; Raval N; Gries C; Hayes JE; Oliveira E; Sniffen J; Allison SL; Herrera V; Jennings DL; Page RL; McDyer JF; Ensor CR
Open Forum Infect Dis; 2021 Oct; 8(10):ofab170. PubMed ID: 34642634
[TBL] [Abstract][Full Text] [Related]
14. [Renin Angiotensin Axis, Angiotensin Converting Enzyme 2 and Coronavirus].
Cano F; Gajardo M; Freundlich M
Rev Chil Pediatr; 2020 Jun; 91(3):330-338. PubMed ID: 32730512
[TBL] [Abstract][Full Text] [Related]
15. Angiotensin-converting enzyme as a new immunologic target for the new SARS-CoV-2.
Hallaj S; Ghorbani A; Mousavi-Aghdas SA; Mirza-Aghazadeh-Attari M; Sevbitov A; Hashemi V; Hallaj T; Jadidi-Niaragh F
Immunol Cell Biol; 2021 Feb; 99(2):192-205. PubMed ID: 32864784
[TBL] [Abstract][Full Text] [Related]
16. [Renin-angiotensin-aldosterone system : brief history and questions related to the COVID-19 pandemic].
Valdes-Socin H; Jouret F; Vroonen L; Scheen AJ; Lancellotti P
Rev Med Liege; 2020 Sup; 75(S1):123-129. PubMed ID: 33211434
[TBL] [Abstract][Full Text] [Related]
17. Kidney and Lung ACE2 Expression after an ACE Inhibitor or an Ang II Receptor Blocker: Implications for COVID-19.
Wysocki J; Lores E; Ye M; Soler MJ; Batlle D
J Am Soc Nephrol; 2020 Sep; 31(9):1941-1943. PubMed ID: 32669323
[No Abstract] [Full Text] [Related]
18. JAK Inhibition as a New Treatment Strategy for Patients with COVID-19.
Seif F; Aazami H; Khoshmirsafa M; Kamali M; Mohsenzadegan M; Pornour M; Mansouri D
Int Arch Allergy Immunol; 2020; 181(6):467-475. PubMed ID: 32392562
[TBL] [Abstract][Full Text] [Related]
19. Focus on clinical practice: angiotensin-converting enzyme 2 and corona virus disease 2019: pathophysiology and clinical implications.
Barillà F; Bassareo PP; Calcaterra G; Romeo F; Mehta JL
J Cardiovasc Med (Hagerstown); 2020 Sep; 21(9):630-633. PubMed ID: 32740495
[TBL] [Abstract][Full Text] [Related]
20. Discovery and characterization of ACE2 - a 20-year journey of surprises from vasopeptidase to COVID-19.
Hooper NM; Lambert DW; Turner AJ
Clin Sci (Lond); 2020 Sep; 134(18):2489-2501. PubMed ID: 32990314
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
